Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 10.00B | 9.68B | 9.84B | 10.17B | 10.98B | 13.44B |
Gross Profit | 7.54B | 7.37B | 7.30B | 7.90B | 8.87B | 11.64B |
EBITDA | 2.79B | 2.83B | 2.38B | 4.36B | 3.92B | 5.73B |
Net Income | 1.53B | 1.63B | 1.16B | 3.05B | 1.56B | 4.00B |
Balance Sheet | ||||||
Total Assets | 28.33B | 28.05B | 26.84B | 24.55B | 23.88B | 24.62B |
Cash, Cash Equivalents and Short-Term Investments | 2.76B | 2.38B | 1.05B | 4.89B | 3.80B | 2.61B |
Total Debt | 6.59B | 6.63B | 7.34B | 6.61B | 7.60B | 7.83B |
Total Liabilities | 10.70B | 11.33B | 12.05B | 11.17B | 12.92B | 13.93B |
Stockholders Equity | 17.63B | 16.72B | 14.80B | 13.40B | 10.90B | 10.70B |
Cash Flow | ||||||
Free Cash Flow | 1.86B | 2.52B | 1.24B | 1.14B | 3.38B | 3.81B |
Operating Cash Flow | 2.12B | 2.88B | 1.55B | 1.38B | 3.64B | 4.23B |
Investing Cash Flow | -1.30B | -799.20M | -4.10B | 1.58B | -563.70M | -608.60M |
Financing Cash Flow | -33.40M | -683.50M | 149.30M | -1.75B | -2.09B | -5.27B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $79.75B | 18.25 | 23.04% | 4.13% | 3.46% | -13.29% | |
75 Outperform | $20.05B | 13.08 | 9.13% | ― | 3.48% | 31.44% | |
75 Outperform | $368.08B | 98.77 | 112.90% | 3.11% | 6.05% | -29.75% | |
68 Neutral | $95.95B | 19.34 | 29.31% | 5.21% | 2.57% | ― | |
68 Neutral | $141.64B | 22.83 | 33.26% | 2.72% | 3.69% | 501.26% | |
67 Neutral | $155.30B | 24.03 | 99.14% | 3.24% | 13.10% | 110.67% | |
51 Neutral | $7.83B | -0.15 | -40.10% | 2.29% | 21.46% | -2.01% |
On June 17, 2025, Biogen Inc. held its 2025 Annual Meeting of Stockholders, where eleven nominees were elected to the Board of Directors for a one-year term. Additionally, stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the advisory vote on executive compensation. These decisions reflect the company’s ongoing governance and financial oversight strategies.
The most recent analyst rating on (BIIB) stock is a Buy with a $294.00 price target. To see the full list of analyst forecasts on Biogen stock, see the BIIB Stock Forecast page.